ArticlePloS one2025
Cancer prevalence and its determinants in Hungary: Analyzing data from the 2009, 2014, and 2019 European Health Interview Surveys.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Dietary Determinants of Diabetes Prevalence: A Cross-Sectional Study in the Hungarian Population.Nutrients · 2026Article
- Clinical and laboratory biomarker correlates of lip, oral cavity, and pharyngeal cancer status in a large retrospective clinical database.Frontiers in oral health · 2026Article
- Design, synthesis, and antiproliferative activity of new 2-amino-pyrano[3,2-RSC advances · 2025Article
- Associations Between Diverse Beverage Consumption Patterns and Oral Health: Evidence from a National Survey in Hungary.Nutrients · 2025Article
- Western Diet and Cognitive Decline: A Hungarian Perspective-Implications for the Design of the Semmelweis Study.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Hungary has the fifth highest cancer incidence rate in the European Union, with an age-standardized rate (ASR) of 336.7 per 100,000 according to GLOBOCAN 2022. Additionally, Hungary holds the highest cancer mortality rate in the EU, with an ASR of 148.1 per 100,000. This study aimed to investigate the sociodemographic, lifestyle, and chronic disease-related factors affecting cancer prevalence in the Hungarian population. Materials and methods Data from the 2009, 2014, and 2019 installments of the European Health Interview Survey conducted in Hungary were pooled, resulting in a representative sample of 16,480 individuals. Weighted multiple logistic regression models were used to analyze the data, with goodness of fit assessed using the Hosmer-Lemeshow test. The best-fitting models were further evaluated using ROC analysis to calculate the Area Under the Curve (AUC) to assess discriminative ability. Results Urban residency was associated with higher cancer odds in 2014 (OR 1.85 [CI: 1.08-3.16]) and the pooled data (OR 1.44 [CI: 1.08-1.9]). Employed individuals had lower odds of cancer (2014: OR 0.34 [CI: 0.16-0.74]; pooled: OR 0.64 [CI: 0.45-0.92]). Among comorbid conditions, peptic ulcer (2009: OR 1.74 [CI: 1.13-2.69]; 2019: OR 3.2 [CI: 1.58-6.47]; pooled: OR 1.83 [CI: 1.31-2.54]) and chronic liver disease (2009: OR 3.52 [CI: 1.73-7.17]; pooled: OR 2.5 [CI: 1.4-4.47]) were significantly associated with higher cancer odds. Reporting bad health was linked to increased cancer risk (2009: OR 2.92 [CI: 1.87-4.58]; 2014: OR 5.52 [CI: 3.23-9.45]; 2019: OR 2.23 [CI: 1.26-3.95]). Conclusion Comorbid conditions such as peptic ulcer and chronic liver disease significantly increase cancer risk in Hungary. Urban residents require targeted preventive measures, and unemployment should be addressed. Early detection through appropriate screening and effective management of comorbid conditions are essential to prevent escalation and reduce overall cancer prevalence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.